Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Parkinson's Disease
Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Parkinson's Disease
This study is to evaluate the safety and efficacy of Umbilical Cord Derived Mesenchymal Stem
 Cells transplantation in Parkinson's disease.
Parkinson's disease (PD) is a neurodegenerative movement disorder，which mainly shows up in
 the elderly. And there is as yet no effective drug treatment. Umbilical cord derived
 mesenchymal stem cells (UC-MSCs) derived from mesoderm owns strong proliferation ability and
 multiple differentiation potential. The investigators used UC-MSCs via intravenous infusion
 to treat PD. With different durations of follow-up, the investigators cleared therapeutic
 effect, the quality of life and prognostic implications of UC-MSCs on PD through the Unified
 Parkinson's Disease Rating Scale (UPDRS), revised Hoehn-Yahr（H-Y） staging, Mini-Mental State
 Examination (MMSE), Hamilton depression scales 24 (HAMD 24), Hamilton Anxiety Scale 14 (HAMA
 14) and Clinical Global Impression (CGI). In this research, the investigators seek new
 therapeutic approaches for PD, and provide clinical evidences for the clinical application of
 UC-MSCs in the future.
Inclusion Criteria:

 1. Age from 40 to 60 years, and no limitation of gender.

 2. Diagnosis of primary Parkinson's disease(PD) according to Movement Disorder Society
 (MDS)-PD criteria established in 2015.

 3. Hoehn-Yahr Stages from I to IV stage.

 4. Drugs for anti Parkinson's disease have been taken over 28 days before entering the
 group.

 5. MMSE score≥25

 6. No antidepressant or antipsychotic drugs were received within 2 weeks.

 7. Understanding and willingness to sign a written informed consent document.

 Exclusion Criteria:

 Patients with PD have to be disqualified from this study if any of the following is
 applicable.

 1. Patients with psychiatric history, but depression.

 2. Suicidal tendency or behavior of patients.

 3. Patients with severe cognitive impairment, chronic organ failure or malignant tumor.

 4. The value of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) was
 1.5 times higher than that of the normal reference; or leucocyte count<1000/μl.

 5. Pregnancy and lactating women.

 6. The patient is taking part in other drug tests, or received other research medication
 within 90 days before entering the group.

 7. Patients who had quit our study could not enter it again.